Literature DB >> 21088061

Uneasy money: the Instituto Carlos Slim de la Salud, tobacco philanthropy and conflict of interest in global health.

Tiffany Burch1, Nathaniel Wander, Jeff Collin.   

Abstract

In May 2007, the Instituto Carso de la Salud-now Instituto Carlos Slim de la Salud (ICSS)-was endowed with US$500 million to focus on priority health issues in Latin America, notably issues of 'globalisation and non-communicable diseases'. ICSS was soon criticised, however, on the grounds that its funding was derived from tobacco industry profits and that its founder Carlos Slim Hélu remained an active industry principal. Collaboration with ICSS was said to run counter to the WHO Framework Convention on Tobacco Control. The Institute's then Executive President Julio Frenk disputed these charges. This research employs an archive of tobacco industry documents triangulated with materials from commercial, media, regulatory and NGO sources to examine the financial relations between Slim and the tobacco industry. The paper analyses Slim's continuing service to the industry and role in ICSS. It demonstrates a prima facie conflict of interest between ICSS's health mission and its founder's involvement in cigarette manufacturing and marketing, reflected on ICSS's website as a resounding silence on issues of tobacco and health. It is concluded that the reliance of international health agencies upon the commercial sector requires more robust institutional policies to effectively regulate conflicts of interest.

Entities:  

Mesh:

Year:  2010        PMID: 21088061      PMCID: PMC4474153          DOI: 10.1136/tc.2010.038307

Source DB:  PubMed          Journal:  Tob Control        ISSN: 0964-4563            Impact factor:   7.552


  18 in total

1.  Speech to the Fifty-First World Health Assembly--Geneva, 13 May 1998.

Authors:  G H Brundtland
Journal:  World Hosp Health Serv       Date:  1998

Review 2.  Implications of the tobacco industry documents for public health and policy.

Authors:  Lisa Bero
Journal:  Annu Rev Public Health       Date:  2001-11-06       Impact factor: 21.981

3.  Reporting conflicts of interest, financial aspects of research, and role of sponsors in funded studies.

Authors:  Phil B Fontanarosa; Annette Flanagin; Catherine D DeAngelis
Journal:  JAMA       Date:  2005-07-06       Impact factor: 56.272

4.  A question of method. The ethics of managing conflicts of interest.

Authors:  Samia A Hurst; Alex Mauron
Journal:  EMBO Rep       Date:  2008-02       Impact factor: 8.807

5.  Mexican billionaire invests millions in Latin American health.

Authors: 
Journal:  Bull World Health Organ       Date:  2007-08       Impact factor: 9.408

Review 6.  Open doorway to truth: legacy of the Minnesota tobacco trial.

Authors:  Richard D Hurt; Jon O Ebbert; Monique E Muggli; Nikki J Lockhart; Channing R Robertson
Journal:  Mayo Clin Proc       Date:  2009-05       Impact factor: 7.616

7.  Group Carso, health philanthropy, and tobacco.

Authors:  Simon Chapman
Journal:  Lancet       Date:  2008-04-12       Impact factor: 79.321

8.  Group Carso, health philanthropy, and tobacco.

Authors:  Julio Frenk
Journal:  Lancet       Date:  2008-04-12       Impact factor: 79.321

Review 9.  Tobacco industry tactics for resisting public policy on health.

Authors:  Y Saloojee; E Dagli
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

Review 10.  Tobacco document research reporting.

Authors:  S M Carter
Journal:  Tob Control       Date:  2005-12       Impact factor: 7.552

View more
  5 in total

1.  Global Fund needs to address conflict of interest.

Authors:  Anna B Gilmore; Gary Fooks
Journal:  Bull World Health Organ       Date:  2012-01-01       Impact factor: 9.408

Review 2.  British American Tobacco's partnership with Earthwatch Europe and its implications for public health.

Authors:  Patricia A McDaniel; Ruth E Malone
Journal:  Glob Public Health       Date:  2011-05-24

3.  Tobacco control, global health policy and development: towards policy coherence in global governance.

Authors:  Jeff Collin
Journal:  Tob Control       Date:  2012-03       Impact factor: 7.552

4.  Global health governance and the commercial sector: a documentary analysis of tobacco company strategies to influence the WHO framework convention on tobacco control.

Authors:  Heide Weishaar; Jeff Collin; Katherine Smith; Thilo Grüning; Sema Mandal; Anna Gilmore
Journal:  PLoS Med       Date:  2012-06-26       Impact factor: 11.069

5.  Transgenic and mutation-based suppression of a berberine bridge enzyme-like (BBL) gene family reduces alkaloid content in field-grown tobacco.

Authors:  Ramsey S Lewis; Harry O Lopez; Steve W Bowen; Karen R Andres; William T Steede; Ralph E Dewey
Journal:  PLoS One       Date:  2015-02-17       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.